U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
21 CFR 202.1(e)(1); 21 U.S.C. 352(n)
What is FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner?
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling. Apply to TV, radio, streaming and online video or audio ads
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
broadcast_tv, broadcast_radio, ctv, ott, streaming_tv, video, audio, broadcast_tv_radio, tv_radio
When does this rule take effect?
2026-10-07
What does this rule require?
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
How can marketing teams comply?
Apply to TV, radio, streaming and online video or audio ads that name a prescription drug and its use.
What is FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner?
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
broadcast_tv, broadcast_radio, ctv, ott, streaming_tv, video, audio, broadcast_tv_radio, tv_radio
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Request a free compliance scan of your homepage and book a time with Warrant.